Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Brigatinib in Pediatric and Young Adult Patients With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

NCT04925609 is registered in ClinicalTrials.gov with Princess Maxima Center for Pediatric Oncology as lead sponsor.

NCT NCT04925609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04925609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Brigatinib in Pediatric and Young Adult Patients With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
Lead sponsor
Princess Maxima Center for Pediatric Oncology
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 18, 2022
Completion date
December 31, 2033
Enrollment
65 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, alk-positive, inflammatory myofibroblastic tumor, other solid tumor